GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (NAS:RIGL) » Definitions » EV-to-Revenue

Rigel Pharmaceuticals (Rigel Pharmaceuticals) EV-to-Revenue

: 1.71 (As of Today)
View and export this data going back to 2000. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Rigel Pharmaceuticals's enterprise value is $200.1 Mil. Rigel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $116.9 Mil. Therefore, Rigel Pharmaceuticals's EV-to-Revenue for today is 1.71.

The historical rank and industry rank for Rigel Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

RIGL' s EV-to-Revenue Range Over the Past 10 Years
Min: -10.66   Med: 5.18   Max: 558.87
Current: 1.71

During the past 13 years, the highest EV-to-Revenue of Rigel Pharmaceuticals was 558.87. The lowest was -10.66. And the median was 5.18.

RIGL's EV-to-Revenue is ranked better than
80.6% of 1031 companies
in the Biotechnology industry
Industry Median: 7.7 vs RIGL: 1.71

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-23), Rigel Pharmaceuticals's stock price is $1.12. Rigel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.67. Therefore, Rigel Pharmaceuticals's PS Ratio for today is 1.67.


Rigel Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Rigel Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.02 5.29 2.41 2.02 2.20

Rigel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 1.79 1.75 1.41 2.20

Competitive Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's EV-to-Revenue falls into.



Rigel Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Rigel Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=200.099/116.882
=1.71

Rigel Pharmaceuticals's current Enterprise Value is $200.1 Mil.
Rigel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $116.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rigel Pharmaceuticals  (NAS:RIGL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Rigel Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.12/0.671
=1.67

Rigel Pharmaceuticals's share price for today is $1.12.
Rigel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.67.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rigel Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Executives
Raul R Rodriguez officer: Sr VP of Bus Dev and Com Ops 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080
David A Santos officer: EVP, Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wolfgang Dummer officer: EVP & CMO 5491 OPTICAL CT., SAN JOSE CA 95138
Dean L Schorno officer: EVP & Chief Financial Officer 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Raymond J. Furey officer: EVP, GC & Corp Sec 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Alison L. Hannah director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Brian L. Kotzin director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Nelson Cabatuan officer: Principal Accounting Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Mayer Eldon C. Iii officer: EVP & Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Stacy Markel officer: EVP Human Resources RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080